Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Confined Solvation Electrolyte for 4.3-V-Class High-Voltage Sodium-Ion Pouch Cells.

ACS nano·2026

Same author

False-positive and true-positive orbital iodine-131 uptake after radioiodine therapy: two contrasting cases clarified by SPECT/CT.

Quantitative imaging in medicine and surgery·2026

Same author

A clinical nomogram incorporating hyperhomocysteinemia for predicting severe delayed encephalopathy after acute carbon monoxide poisoning: a retrospective single-center study.

Frontiers in medicine·2026

Same author

High Sensitivity ctDNA Analysis Using a Novel Panel and NOIR-SS Technology for Monitoring Advanced Urothelial Carcinoma.

Cancer medicine·2026

Same author

Evaluation of Presacral Vascular Anatomy Using Contrast-Enhanced 3D-CT for Surgical Planning in Endoscopic Sacrocolpopexy.

Diagnostics (Basel, Switzerland)·2026

Same author

Phylogenetic Analyses of <i>RdRp</i> Region and <i>VP1</i> Gene in Human Norovirus Genotype GII.17[P17] Variants.

Microorganisms·2026

Search research articles

Related Experiment Video

Updated: Jul 2, 2026

In Vitro Differentiation of Naive CD4+ T Cells into Pathogenic Th17 Cells in Mouse

In Vitro Differentiation of Naive CD4⁺ T Cells into Pathogenic Th17 Cells in Mouse

Published on: October 25, 2024

IL-17-driven tumor cell-intrinsic inflammatory programming creates an immunotherapy-permissive microenvironment.

Kosuke Murakami¹, Shiki Takamura^2,3, Chiho Miyagawa¹

¹Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, 1-14-1, Miharadai, Minami-Ku, Sakai, Osaka, 590-0197, Japan.

Molecular Cancer

|July 1, 2026

Summary

Interleukin-17 (IL-17) can make ovarian clear cell carcinoma tumors more responsive to immunotherapy by activating inflammatory signals. This finding suggests IL-17 could guide personalized cancer treatment strategies.

Keywords:

CD4 Clear cell carcinoma IL-17 Immunotherapy NF-κB Ovarian cancer RORC Th17

More Related Videos

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

Related Experiment Videos

Last Updated: Jul 2, 2026

In Vitro Differentiation of Naive CD4+ T Cells into Pathogenic Th17 Cells in Mouse

In Vitro Differentiation of Naive CD4⁺ T Cells into Pathogenic Th17 Cells in Mouse

Published on: October 25, 2024

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

Area of Science:

Oncology
Immunology
Molecular Biology

Background:

Immune checkpoint inhibitors (ICIs) show limited efficacy in unselected ovarian cancer patients.
Ovarian clear cell carcinoma (OCCC) harbors a subset responsive to ICIs, indicating underlying biological heterogeneity.
Identifying this immunologically responsive subset is crucial for improving treatment outcomes.

Purpose of the Study:

To investigate the role of IL-17 in OCCC immune microenvironment.
To determine if IL-17 influences OCCC responsiveness to immune checkpoint blockade.
To elucidate the mechanisms by which IL-17 affects tumor cells and immune cells in OCCC.

Main Methods:

Immunohistochemical profiling of tumor-infiltrating immune cells in OCCC.
Transcriptomic analysis of human OCCC cohorts (n=180).
Functional studies in a syngeneic OCCC mouse model, including single-cell RNA sequencing.

Main Results:

OCCC exhibits an immune-sparse microenvironment with enriched CD4+ T cells and heterogeneous RORC expression.
A subset (5%) of OCCC with high IL-17A expression showed a T cell-inflamed gene profile.
IL-17 activated inflammatory pathways in OCCC cells, increasing T cell recruitment and activation, and enhancing anti-PD-L1 therapy efficacy in a mouse model.

Conclusions:

IL-17-driven inflammatory programming in OCCC cells remodels the tumor microenvironment towards an immunotherapy-permissive state.
IL-17 responsiveness is a key mechanism influencing immune checkpoint sensitivity in OCCC.
These findings support IL-17 as a potential biomarker and therapeutic target for guiding immunotherapy strategies in OCCC.